Form 4: Surgery Partners CEO Jason Evans Acquires 56,446 Shares of Common Stock

Surgery Partners CEO Jason Eric Evans acquired 56,446 shares of common stock on February 28, 2024, through a restricted stock award.

Summary

• On February 28, 2024, Jason Eric Evans, the CEO of Surgery Partners, Inc., acquired 56,446 shares of common stock.
• The acquisition was in the form of restricted stock awards (RSAs) granted on the same date.
• The price per share was $31.18.
• The RSAs vest in three equal annual installments starting on the first anniversary of the grant date.
• Following the transaction, Evans directly owns 475,564 shares of Surgery Partners, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The CEO receiving stock awards is generally a good sign, indicating confidence in the company's future. The vesting schedule promotes long-term alignment.

Positives

• The CEO's acquisition of shares demonstrates confidence in the company's future prospects.
• The vesting schedule of the RSAs aligns the CEO's interests with the long-term performance of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSAs suggests a multi-year commitment from the CEO.

Industry Context

This type of stock award is common in the healthcare industry to incentivize and retain key executives. It aligns management's interests with shareholder value.

Comparison to Industry Standards

• Stock grants to CEOs are a standard practice across the healthcare industry.
• Companies like HCA Healthcare and Tenet Healthcare also use stock-based compensation to incentivize their executives.
• The vesting schedule of three years is also a common practice to ensure long-term commitment.

Stakeholder Impact

• The CEO's increased stake in the company could positively influence shareholder confidence.
• The vesting schedule incentivizes the CEO to focus on long-term value creation, benefiting shareholders.

Key Dates